The relationship between chemokines CCL2, CCL3, and CCL4 with the tumor microenvironment and tumor-associated macrophage markers in colorectal cancer

A complex network of chemokines can influence cancer progression with the recruitment and activation of hematopoietic cells, including macrophages to the supporting tumor stroma promoting carcinogenesis and metastasis. The aim of this study was to investigate the relation between tissue and plasma chemokine levels involved in macrophage recruitment with tumor-associated macrophage profile markers and clinicopathological features such as tumor–node–metastases stage, desmoplasia, tumor necrosis factor-α, and vascular endothelial growth factor plasma content. Plasma and tumor/healthy mucosa were obtained from Chilean patients undergoing colon cancer surgery. Chemokines were evaluated from tissue lysates (CCL2, CCL3, CCL4, CCL5, and CX3CL1) by Luminex. Statistical analysis was performed using Wilcoxon match-paired test (p < 0.05). Macrophage markers (CD68, CD163, and iNOS) were evaluated by immunohistochemistry samples derived from colorectal cancer patients. Correlation analysis between chemokines and macrophage markers and clinicopathological features were performed using Spearman’s test. Plasmatic levels of chemokines and inflammatory mediators’ vascular endothelial growth factor and tumor necrosis factor-α were evaluated by Luminex. Tumor levels of CCL2 (mean ± standard deviation = 530.1 ± 613.9 pg/mg), CCL3 (102.7 ± 106.0 pg/mg), and CCL4 (64.98 ± 48.09 pg/mg) were higher than those found in healthy tissue (182.1 ± 116.5, 26.79 ± 22.40, and 27.06 ± 23.69 pg/mg, respectively p < 0.05). The tumor characterization allowed us to identify a positive correlation between CCL4 and the pro-tumor macrophages marker CD163 (p = 0.0443), and a negative correlation of iNOS with desmoplastic reaction (p = 0.0467). Moreover, we identified that tumors with immature desmoplasia have a higher CD163 density compared to those with a mature/intermediated stromal tissue (p = 0.0288). Plasmatic CCL4 has shown a positive correlation with inflammatory mediators (tumor necrosis factor-α and vascular endothelial growth factor) that have previously been associated with poor prognosis in patients. In conclusion High expression of CCL4 in colon cancer could induce the infiltration of tumor-associated macrophages and specifically a pro-tumor macrophage profile (CD163+ cells). Moreover, plasmatic chemokines could be considered inflammatory mediators associated to CRC progression as well as tumor necrosis factor-α and vascular endothelial growth factor. These data reinforce the idea of chemokines as potential therapeutic targets or biomarker in CRC.

[1]  F. M. Gabhann,et al.  Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer , 2007, British Journal of Cancer.

[2]  P. Allavena,et al.  Expression of chemokines and chemokine receptors in human colon cancer. , 2009, Methods in enzymology.

[3]  N. Mukaida,et al.  Chemokines in Cancer Development and Progression and Their Potential as Targeting Molecules for Cancer Treatment , 2014, Mediators of inflammation.

[4]  J. Pober,et al.  Tumour necrosis factor and cancer , 2013, The Journal of pathology.

[5]  T. Langmann,et al.  Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro‐ and antiinflammatory stimuli , 2000, Journal of leukocyte biology.

[6]  A. Sica,et al.  Macrophage plasticity and polarization in tissue repair and remodelling , 2013, The Journal of pathology.

[7]  J. Carethers,et al.  Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. , 2015, Gastroenterology.

[8]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[9]  Silvano Sozzani,et al.  The chemokine system in diverse forms of macrophage activation and polarization. , 2004, Trends in immunology.

[10]  E. Kuipers,et al.  Colorectal cancer screening: a global overview of existing programmes , 2015, Gut.

[11]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[12]  Ruo-Pan Huang,et al.  Tumor-induced perturbations of cytokines and immune cell networks. , 2014, Biochimica et biophysica acta.

[13]  H. Nielsen,et al.  Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma , 2002, British Journal of Cancer.

[14]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[15]  U. Hopt,et al.  Chemokines in human colorectal carcinoma. , 2005, Anticancer research.

[16]  Ying Liu,et al.  Radioactive 125I seeds inhibit cell growth and epithelial-mesenchymal transition in human glioblastoma multiforme via a ROS-mediated signaling pathway , 2015, BMC Cancer.

[17]  A. Mantovani,et al.  Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization: Lessons and Open Questions , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Z. Halpern,et al.  Tumor macrophages are pivotal constructors of tumor collagenous matrix , 2016, The Journal of experimental medicine.

[19]  D. McMillan,et al.  Cancer and systemic inflammation: treat the tumour and treat the host , 2014, British Journal of Cancer.

[20]  D. Wågsäter,et al.  Circulating inflammatory factors associated with worse long-term prognosis in colorectal cancer , 2017, World journal of gastroenterology.

[21]  Charles James Kirkpatrick,et al.  Histopathological features predict metastatic potential in locally advanced colon carcinomas , 2015, BMC Cancer.

[22]  F. López-Köstner,et al.  Increasing crude and adjusted mortality rates for colorectal cancer in a developing South American country , 2013, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[23]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[24]  P. Allavena,et al.  Circulating Inflammatory Mediators as Potential Prognostic Markers of Human Colorectal Cancer , 2016, PloS one.

[25]  Yuan Zhang,et al.  Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. , 2013, European journal of cancer.

[26]  Hideki Ueno,et al.  Histologic Categorization of Desmoplastic Reaction: Its Relevance to the Colorectal Cancer Microenvironment and Prognosis , 2015, Annals of Surgical Oncology.

[27]  H. Ueno,et al.  Prognostic impact of histological categorisation of epithelial–mesenchymal transition in colorectal cancer , 2014, British Journal of Cancer.

[28]  M. Provencio,et al.  Cancer‐associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients , 2013, Cancer science.

[29]  M. Kinouchi,et al.  Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. , 2012, Hepato-gastroenterology.

[30]  A. B. Lyons,et al.  Absence of Tumor Necrosis Factor Supports Alternative Activation of Macrophages in the Liver after Infection with Leishmania major , 2018, Front. Immunol..

[31]  A. Darzi,et al.  Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer , 2007, Clinical & Experimental Metastasis.

[32]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[33]  P. Gibbs,et al.  Systemic Inflammation - Impact on Tumor Biology and Outcomes in Colorectal Cancer , 2015 .

[34]  B. Pitard,et al.  CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma , 2011, PloS one.

[35]  S. Shi,et al.  Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages , 2015, BMC Cancer.

[36]  M. Barbosa,et al.  Decellularized human colorectal cancer matrices polarize macrophages towards an anti-inflammatory phenotype promoting cancer cell invasion via CCL18. , 2017, Biomaterials.

[37]  Klaus Pfeffer,et al.  Biological functions of tumor necrosis factor cytokines and their receptors. , 2003, Cytokine & growth factor reviews.

[38]  R. Bloigu,et al.  The relationships between serum cytokine levels and tumor infiltrating immune cells and their clinical significance in colorectal cancer , 2016, International journal of cancer.

[39]  P. Allavena,et al.  The Fractalkine-Receptor Axis Improves Human Colorectal Cancer Prognosis by Limiting Tumor Metastatic Dissemination , 2016, The Journal of Immunology.

[40]  J. Goodwin,et al.  Plasma cytokine levels in a population-based study: relation to age and ethnicity. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[41]  S. Gordon,et al.  The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.

[42]  Matthew J. Craig,et al.  CCL2 and Interleukin-6 Promote Survival of Human CD11b+ Peripheral Blood Mononuclear Cells and Induce M2-type Macrophage Polarization* , 2009, The Journal of Biological Chemistry.

[43]  M. De la Fuente,et al.  Chronic Inflammation and Cytokines in the Tumor Microenvironment , 2014, Journal of immunology research.

[44]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[45]  Marco Erreni,et al.  Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer , 2011, Cancer Microenvironment.

[46]  J. Väyrynen,et al.  Detailed analysis of inflammatory cell infiltration in colorectal cancer , 2013, British Journal of Cancer.

[47]  G. de Toma,et al.  Desmoplasia Influenced Recurrence of Disease and Mortality in Stage III Colorectal Cancer within Five Years after Surgery and Adjuvant Therapy , 2017, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[48]  M. Raes,et al.  M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide , 2015, BMC Cancer.

[49]  E. Cukierman,et al.  Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. , 2015, Trends in biotechnology.

[50]  I. Talbot,et al.  Histological categorisation of fibrotic cancer stroma in advanced rectal cancer , 2004, Gut.

[51]  C. Appleyard,et al.  Colonic macrophage polarization in homeostasis, inflammation, and cancer. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[52]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[53]  T. Vlaykova,et al.  The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients’ survival , 2013, Journal of Molecular Histology.

[54]  Noam Brown,et al.  The role of tumour‐associated macrophages in tumour progression: implications for new anticancer therapies , 2002, The Journal of pathology.

[55]  N. Minagawa,et al.  Relationships between tumor-associated macrophages and clinicopathological factors in patients with colorectal cancer. , 2002, Anticancer research.

[56]  Yukio Fujiwara,et al.  Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.

[57]  K. Matsushima,et al.  Crucial involvement of the CCL3‐CCR5 axis‐mediated fibroblast accumulation in colitis‐associated carcinogenesis in mice , 2014, International journal of cancer.

[58]  Soo-Ki Kim,et al.  Association of serum and intratumoral cytokine profiles with tumor stage and neutrophil lymphocyte ratio in colorectal cancer. , 2014, Anticancer research.

[59]  B. Kołodziej,et al.  Protein Expression and Genetic Variation of IL32 and Association with Colorectal Cancer in Swedish Patients. , 2018, Anticancer Research.

[60]  E. Giannoni,et al.  Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression , 2014, Oncogene.

[61]  M. Roussel,et al.  TNF Counterbalances the Emergence of M2 Tumor Macrophages. , 2015, Cell reports.

[62]  M. Koch,et al.  Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.